Maarten Slagter

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction”.

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Cell(2020)10.1016/j.cell.2020.09.015

N/A

0DataRank · unranked

541 citations

Marit M. van Buuren, Kristen K. Dang, Vanessa M. Hubbard-Lucey, Kathleen C. F. Sheehan, Katie M. Campbell +95 more

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of Oncology(2021)10.1016/j.annonc.2021.02.006

N/A

0DataRank · unranked

1067 citations

P.G. Pilié, N.U. Rashid, Leonie Voorwerk, Maarten Slagter, Marleen Kok +11 more

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

Annals of Oncology(2021)10.1016/j.annonc.2021.06.017

N/A

0DataRank · unranked

2 citations

P.G. Pilié, N.U. Rashid, Leonie Voorwerk, Maarten Slagter, Marleen Kok +8 more

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

Annals of Oncology(2022)10.1016/j.annonc.2022.07.009

N/A

0DataRank · unranked

8 citations

P.G. Pilié, N.U. Rashid, Leonie Voorwerk, Maarten Slagter, Marleen Kok +8 more